{"groups":[{"description":"160 milligrams (mg) Selpercatinib administered orally (PO) twice daily (BID).\n\nAdolescent Dose: 92 milligrams per square meter (mg/m2) BID (not to exceed 160 mg BID).","id":"FG000","title":"Selpercatinib - Treatment A (TRT A)"},{"description":"140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice.\n\nCabozantinib Adolescent Dose: 40 mg/m2.\n\nVandetanib Adolescent Dose:\n\n* 0.7 - \\<0.9 - 100 mg every other day (QOD)\n* 0.9 - \\<1.2 - 100 mg QD\n* 1.2 - \\<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg\n* ≥1.6 - 200 QD","id":"FG001","title":"Cabozantinib or Vandetanib - Treatment B (TRT B)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"175"},{"groupId":"FG001","numSubjects":"40"}],"type":"On Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"193"},{"groupId":"FG001","numSubjects":"98"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"193"},{"groupId":"FG001","numSubjects":"97"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"56"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"175"},{"groupId":"FG001","numSubjects":"42"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"If a participant has a recorded death on study, or is alive and being followed but off treatment, then the participant can be considered to be study completer.\n\nParticipants randomized to the Cabozantinib or Vandetanib arm will be allowed to crossover to receive the investigational product at the time of Blinded Independent Committee Review (BICR) confirmed radiographic progression."}